Xeris' G-Pen increases plasma glucose in Phase III pediatric hypoglycemia

Xeris Pharmaceuticals Inc. (NASDAQ:XERS) said its G-Pen glucagon injection rescue

Read the full 107 word article

Trial Subscription

Get a two-week free trial subscription to BioCentury

SIGN UP

Article Purchase

This article may not be distributed to non-subscribers
More Info >PURCHASE